Identification of Recurrent Activating <i>HER2</i> Mutations in Primary Canine Pulmonary Adenocarcinoma.

Abstract

Naturally occurring primary canine lung cancers share clinicopathologic features with human lung cancers in never-smokers, but the genetic underpinnings of canine lung cancer are unknown. We have charted the genomic landscape of canine lung cancer and performed functional characterization of novel, recurrent <i>HER2 (ERBB2)</i> mutations occurring in canine pulmonary adenocarcinoma (cPAC). We performed multiplatform genomic sequencing of 88 primary canine lung tumors or cell lines. Additionally, in cPAC cell lines, we performed functional characterization of HER2 signaling and evaluated mutation-dependent HER2 inhibitor drug dose-response. We discovered somatic, coding <i>HER2</i> point mutations in 38% of cPACs (28/74), but none in adenosquamous (cPASC, 0/11) or squamous cell (cPSCC, 0/3) carcinomas. The majority (93%) of <i>HER2</i> mutations were hotspot V659E transmembrane domain (TMD) mutations comparable to activating mutations at this same site in human cancer. Other <i>HER2</i> mutations were located in the extracellular domain and TMD. <i>HER2</i> ^V659E was detected in the plasma of 33% (2/6) of dogs with localized <i>HER2</i> ^V659E tumors. <i>HER2</i> ^V659E cPAC cell lines displayed constitutive phosphorylation of AKT and significantly higher sensitivity to the HER2 inhibitors lapatinib and neratinib relative to <i>HER2</i>-wild-type cell lines (IC₅₀ < 200 nmol/L in <i>HER2</i> ^V659E vs. IC₅₀ > 2,500 nmol/L in <i>HER2</i> ^WT). This study creates a foundation for molecular understanding of and drug development for canine lung cancer. These data also establish molecular contexts for comparative studies in dogs and humans of low mutation burden, never-smoker lung cancer, and mutant HER2 function and inhibition.